HK1246367A1 - 转移性疾病的基因标记预测 - Google Patents

转移性疾病的基因标记预测 Download PDF

Info

Publication number
HK1246367A1
HK1246367A1 HK18105968.7A HK18105968A HK1246367A1 HK 1246367 A1 HK1246367 A1 HK 1246367A1 HK 18105968 A HK18105968 A HK 18105968A HK 1246367 A1 HK1246367 A1 HK 1246367A1
Authority
HK
Hong Kong
Prior art keywords
metastatic disease
gene signatures
signatures predictive
expression level
cancer
Prior art date
Application number
HK18105968.7A
Other languages
English (en)
Chinese (zh)
Inventor
Steven Walker
Laura Hill
Andrena MCCAVIGAN
Sinead DONEGAN
Timothy Davison
Richard Kennedy
Denis Paul Harkin
Bethanie PRICE
Original Assignee
Almac Diagnostic Services Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostic Services Limited filed Critical Almac Diagnostic Services Limited
Publication of HK1246367A1 publication Critical patent/HK1246367A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18105968.7A 2015-06-17 2016-06-17 转移性疾病的基因标记预测 HK1246367A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
GB201510684 2015-06-17
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease

Publications (1)

Publication Number Publication Date
HK1246367A1 true HK1246367A1 (zh) 2018-09-07

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105968.7A HK1246367A1 (zh) 2015-06-17 2016-06-17 转移性疾病的基因标记预测

Country Status (8)

Country Link
US (1) US20210254166A1 (enExample)
EP (1) EP3310927B1 (enExample)
JP (1) JP2018527886A (enExample)
CN (1) CN108513587A (enExample)
CA (1) CA2989388A1 (enExample)
GB (1) GB201510684D0 (enExample)
HK (1) HK1246367A1 (enExample)
WO (1) WO2016203262A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
CA3168490A1 (en) * 2020-01-21 2021-07-29 Miha STAJDOHAR Evaluating the robustness and transferability of predictive signatures across molecular biomarker datasets
EP4133491A1 (en) 2020-04-09 2023-02-15 Tempus Labs, Inc. Predicting likelihood and site of metastasis from patient records
CN116096899A (zh) 2020-06-29 2023-05-09 Ionis制药公司 调节plp1的化合物和方法
US20230390367A1 (en) * 2020-10-19 2023-12-07 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
KR0148265B1 (ko) 1988-12-16 1998-10-15 에프.지이.엠 헤르만스 자가-지속 서열 복제 시스템
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP1474528A4 (en) * 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
EP1604014A4 (en) * 2003-03-20 2008-03-26 Dana Farber Cancer Inst Inc GENE EXPRESSION IN BREAST CANCER
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
AU2005300688B2 (en) 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
JP2010535529A (ja) 2007-08-13 2010-11-25 アルマック ダイアグノスティックス リミテッド マイクロアレイ製造用３’ベースシークエンシング手法
WO2010068839A2 (en) * 2008-12-11 2010-06-17 The Regents Of The University Of California Membrane compositions and methods for making and using them
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
EP2709614A4 (en) * 2011-05-17 2015-04-15 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
US20150218646A1 (en) * 2012-07-20 2015-08-06 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer

Also Published As

Publication number Publication date
WO2016203262A3 (en) 2017-01-26
EP3310927A2 (en) 2018-04-25
EP3310927B1 (en) 2021-05-19
CA2989388A1 (en) 2016-12-22
CN108513587A (zh) 2018-09-07
JP2018527886A (ja) 2018-09-27
GB201510684D0 (en) 2015-08-05
US20210254166A1 (en) 2021-08-19
WO2016203262A2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
HK1246367A1 (zh) 转移性疾病的基因标记预测
JO3681B1 (ar) استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr
BR112017025254A2 (pt) ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento?
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
MX2017007535A (es) Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
MX2016014624A (es) Metodos para el tratamiento de enfermedad inflamatoria del intestino.
BR112016006635A2 (pt) método de seleção dentre uma pluralidade de planos de tratamento para tratar um tumor, e, produto de computador
WO2016077366A8 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
EA200900927A1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
WO2014145751A3 (en) Targeted therapies for cancer
EP3495502A3 (en) Biomarkers for premature birth
RU2018104570A (ru) Экспрессия fgfr и чувствительность к ингибитору fgfr
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
EA201890649A1 (ru) Новые биомаркеры и способы лечения рака
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
WO2018046770A3 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
Ghosh et al. Selection of genes mediating certain cancers, using a neuro-fuzzy approach
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal